#Sweden #Stockholm #Board of Directors #Alzheimer's Disease #BioArctic AB

BioArctic AB Proposes New Board Members

On March 27, 2026, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) revealed the nominations for its board of directors ahead of the Annual General Meeting scheduled for May 28, 2026. The Nomination Committee has presented a plan to maintain a board of eight members.

The Nomination Committee has emphasized the importance of experienced leadership by proposing the re-election of prominent board members, including Eugen Steiner, Cecilia Edström, Anna-Lena Engwall, Lars Lannfelt, Lotta Ljungqvist, and Mikael Smedeby. In addition to these seasoned members, the committee seeks to welcome two new faces: Philip Scheltens and Linda Nilsson, both providing unique expertise to the board.

Eugen Steiner is recommended for re-election as chairperson of the board, reinforcing continuity and stability in leadership.

Notable Profiles of the New Nominees

Philip Scheltens

Philip Scheltens stands out as one of the most distinguished experts in Alzheimer's research. His extensive background includes diplomatic training at Amsterdam’s VU University, where he earned his MD in 1984 and PhD in 1993. Having established the Alzheimer Center at Amsterdam University Medical Centers, he led it until 2022, showing a deep commitment to combating dementia. His work at EQT Group, where he manages the Dementia Fund, reflects his ongoing dedication to tackling Alzheimer's disease. Scheltens has significantly contributed to numerous clinical studies, underscoring his pivotal role in dementia research and treatment.

Linda Nilsson

Linda Nilsson arrives with a robust history in the global retail landscape, particularly with the international fashion conglomerate HM, where she honed her leadership skills over two decades. Currently serving as the Head of Product Operations Development, she oversees a vast team and plays a critical role in strategic decision-making and operational governance. Previously, Linda held the title of Global Managing Director for Womenswear, directing a substantial business sector that generated around 40 billion SEK in annual revenue. Her expertise in strategy, transformation, and operational effectiveness positions her as an asset to BioArctic's board.

Changes in Board Composition

The Nomination Committee also confirmed that Pär Gellerfors will not seek re-election, paving the way for his daughter, Linda Nilsson, to take his place representing their family's holding company, Ackelsta AB.

The nominations reflect not only a commitment to maintaining board stability but also an intention to bring in fresh perspectives that align with BioArctic's mission to innovate in the biopharma space, particularly in neurodegenerative disease treatment.

Upcoming Shareholder Engagement

Details about the elected members, the Nomination Committee’s recommendations, and insights into their qualifications will soon be made available on BioArctic's official website. The notice for the Annual General Meeting is expected to be published on April 21, 2026. This engagement offers shareholders an opportunity to understand the dynamics of the board and contribute to the strategic direction of the company.

The Nomination Committee, appointed based on principles endorsed in 2024, consists of key representatives from significant shareholders, collectively holding approximately 57% of the shares and 83% of the voting power.

As BioArctic prepares for this pivotal meeting, the proposed changes to the board suggest a sound strategy aimed at strengthening its leadership team while navigating the complexities of Alzheimer’s disease treatment.

About BioArctic AB

Founded as a pioneering biopharma company, BioArctic AB is renowned for its innovative approaches in treating neurodegenerative diseases. The firm is particularly recognized for its breakthrough product, Leqembi® (lecanemab), which is the first approved drug shown to slow cognitive decline in early Alzheimer's patients. Through partnerships and various research endeavors, BioArctic continues to pursue advancements that promise to improve patient care and outcomes in the neurodegenerative field.

For more information, visit www.bioarctic.com.